Advertisement

Current Diabetes Reports

, 19:128 | Cite as

USA Vs Europe: Who Is Leading the Diabetes Tech Race?

  • Gonzalo J. Acosta
  • Spandana Brown
  • Ashkan M. Zand
  • Abhishek KansaraEmail author
  • Archana Sadhu
Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)
  • 53 Downloads
Part of the following topical collections:
  1. Topical Collection on Health Care Delivery Systems and Implementation in Diabetes

Abstract

Purpose of Review

To highlight global advancements in diabetes technology and compare available technologies and device approval processes in the USA and Europe and their impact on safety and innovation.

Recent Findings

The last two decades have seen a rapid growth in diabetes technology driven by the impetus to improve glycemic control, avoid complications of insulin therapy, improve quality of life, and hand more autonomy to individuals with diabetes. Meanwhile, changes to regulatory processes in the USA and Europe aim to facilitate entry of new devices into the marketplace.

Summary

Major strides have been made in digitization of insulin pens, continuous glucose monitors and their integration with insulin pumps, automated insulin delivery systems, and closed-loop insulin pump systems. The centralized regulatory body in the USA and more decentralized approval bodies in Europe have led to differences in the rate of market availability of diabetes devices. While both US and Europe systems have different advantages and disadvantages in device approval, they continue to struggle with balancing accelerated device access with adequate clinical evidence and monitoring to ensure safety of such devices.

Keywords

Diabetes technology Europe United States Insulin pump Continuous glucose monitor Approval process 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human/Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Lau DCW. Diabetes technology and devices transform the lives of people with diabetes. Can J Diabetes. 2015 Jun;39(3):174–5.CrossRefGoogle Scholar
  2. 2.
    Karamanou M, Protogerou A, Tsoucalas G, Androutsos G, Poulakou-Rebelakou E. Milestones in the history of diabetes mellitus: the main contributors. World J Diabetes. 2016 Jan;7(1):1–7.CrossRefGoogle Scholar
  3. 3.
    Hirsch IB. Introduction: history of glucose monitoring. Role of continuous glucose monitoring in diabetes treatment. 1st ed.: American Diabetes Association; 2018.Google Scholar
  4. 4.
    Companion Medical. InPen reusable pen injector user guide. 2017; Available at: https://www.companionmedical.com/wp-content/uploads/inpen-user-guide.pdf. Accessed June 13, 2019.
  5. 5.
    Diamesco. Pendiq 2.0 User Manual. 2017; Available at: https://pendiq.com/wp-content/uploads/2017/05/Pendiq-2-0-English-User-Manual_2017_09_01.pdf. Accessed June 14, 2019.
  6. 6.
    Diabnext. Clipsulin Welcome Guide. 2018; Available at: https://www.diabnext.com/wp-content/uploads/2018/12/CLIPSULINC3-English.pdf. Accessed June 14, 2019.
  7. 7.
    The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009;32(11):2047–9.CrossRefGoogle Scholar
  8. 8.
    van Beers CA, DeVries JH. Continuous glucose monitoring: impact on hypoglycemia. J Diabetes Sci Technol. 2016;10(6):1251–8.CrossRefGoogle Scholar
  9. 9.••
    Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised, controlled trial. Lancet. 2018;391(10128):1367–77. This study showed that usage of CGM reduced the number of hypoglycemic events in patients with type 1 diabetes on insulin injections with hypoglycemia unawareness or severe hypoglycemia. CrossRefGoogle Scholar
  10. 10.
  11. 11.
  12. 12.
    Dexcom. Dexcom G6 CGM System User Guide. 2019; Available at: https://s3-us-west-2.amazonaws.com/dexcompdf/G6-CGM-Users-Guide.pdf. Accessed June 15, 2019.
  13. 13.
    Abbott Diabetes Care. FreeStyle Libre 14 Day User’s Manual. 2018; Available at: https://freestyleserver.com/Payloads/IFU/2018/ART39764-001_rev-A-Web.pdf. Accessed June 15, 2019.
  14. 14.
    Abbott Diabetes Care. FreeStyle Libre 2 Webpage. 2019; Available at: https://www.freestylelibre.de/libre/. Accessed June 28, 2019.
  15. 15.
    Senseonics. Eversense User Guide. 2019; Available at: http://resources.eversensediabetes.com/resource/patient/eversense-cgm-user-guide. Accessed June 15, 2019.
  16. 16.
    Senseonics. Eversense XL User Guide. 2018; Available at: https://ous.eversensediabetes.com/wp-content/uploads/2019/04/LBL-1402-25-101_Rev_A_Eversense_User_Guide_mmol_UK.pdf. Accessed June 15, 2019.
  17. 17.
    Medtrum. A6 TouchCare Insulin Management System User Guide. 2019; Available at: https://www.medtrum.com/pdf/0911/UG882111GB%C2%A0A6%C2%A0TouchCare%C2%AE%C2%A0System%C2%A0Touchscreen%C2%A0User%C2%A0Guide%C2%A0V2.23-20190513.pdf. Accessed June 15, 2019.
  18. 18.
    Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. (2010, 1).Google Scholar
  19. 19.
    Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010 07/22;363(4):311–20.CrossRefGoogle Scholar
  20. 20.
    Medtronic. MiniMed 670G System User Guide. 2017; Available at: https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/MiniMed-670G-System-User-Guide.pdf. Accessed June 15, 2019.
  21. 21.
  22. 22.
  23. 23.
    Tandem Diabetes Care. t:slim X2 Insulin Pump User Guide. 2019; Available at: https://www.tandemdiabetes.com/docs/default-source/product-documents/t-slim-x2-insulin-pump/user-guide_tslimx2_basal_iq.pdf?sfvrsn=eeb230d7_22. Accessed June 15, 2019.
  24. 24.
    Insulet Corporation. Omnipod Insulin Management System User Guide. 2017; Available at: https://www.myomnipod.com/sites/default/files/inline-files/17845-5A%20Guide%2C%20Eros%20US%20User%20Guide%20Rev%20B%20-%20View.pdf. Accessed June 16, 2019.
  25. 25.
    Insulet Corporation. Omnipod DASH Insulin Management System User Guide. 2018; Available at: https://www.myomnipod.com/sites/default/files/media/documents/18296-ENG-AW%20Rev%20B_USA%20DASH%20User%20Guide.pdf. Accessed June 16, 2019.
  26. 26.
    SOOIL Development. Dana Diabecare Insulin Pump Therapy. 2018; Available at: http://www.sooil.com/eng/product/. Accessed June 16, 2019.
  27. 27.
    Medtrum. P6 EasyPatch Disposable Pump. 2019; Available at: https://www.medtrum.com/P6.html. Accessed June 16, 2019.
  28. 28.
    Roche Diabetes Care. Accu-Chek Insulin Pump Systems. 2019; Available at: https://www.accu-chek.co.uk/insulin-pumps. Accessed June 16, 2019.
  29. 29.
    Ypsomed. mylife YpsoPump User Guide. 2017; Available at: file:///C:/Users/Owner/Downloads/YPU_eIFU_REF_700009424_UK-en_V01.pdf. Accessed June 16, 2019.Google Scholar
  30. 30.
    ViCentra BV. Kaleido Guidebook. 2018; Available at: https://s3-eu-west-1.amazonaws.com/assets.hellokaleido.com/Kaleido-Guidebook_UK_180521.pdf?mtime=20180719114754. Accessed June 16, 2019.
  31. 31.
    Valeritas. V-Go Wearable Insulin Delivery Device Instructions for Patient Use. 2018; Available at: https://44yunigub221yppu525xpeh2-wpengine.netdna-ssl.com/wp-content/uploads/2018/06/ART-037_Rev-J_V-GoUpdatedIFU_05252018_FNL_LowRes.pdf. Accessed June 16, 2019.
  32. 32.
    Zhang S. ‘Looping’ created an underground insulin-pump market. The Atlantic 2019 April 29.Google Scholar
  33. 33.
    Diabeloop. Products: DBLG1 System. 2019; Available at: https://www.diabeloop.com/products. Accessed July 5, 2019.
  34. 34.
    Garg SK, Shah V. Closed-loop insulin delivery systems for patients with diabetes. Lancet Digital Health. 2019 May;1(1):e2–3.CrossRefGoogle Scholar
  35. 35.
    Tidepool. Tidepool Loop overview. 2019; Available at: https://www.tidepool.org/loop. Accessed July 8, 2019.
  36. 36.
    Johnson JA. FDA Regulation of Medical Devices 2016;R42130.Google Scholar
  37. 37.
    US Food and Drug Administration. Consumers (Medical Devices). 2019; Available at: https://www.fda.gov/medical-devices/resources-you-medical-devices/consumers-medical-devices. Accessed June 30, 2019.
  38. 38.
    Emmett J, Dodsworth N. Medical Device Development: Pathways to Approval in the U.S. and the EU. 2017; Available at: https://premier-research.com/wp-content/uploads/conf/2017/05/PRWP27_MedDevice_0617_web_b.pdf. Accessed June 30, 2019.
  39. 39.
    Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2015 Apr;38(4):716–22.PubMedGoogle Scholar
  40. 40.
    Van Norman GA. Drugs, devices, and the FDA: part 2: an overview of approval processes: FDA approval of medical devices JACC Basic Transl Sci 2016 Jun 27;1(4):277–287.Google Scholar
  41. 41.
    Van Norman GA. Drugs and devices: comparison of European and U.S. approval processes. JACC: Basic to Trans Sci. 2016;1(5):399–412.Google Scholar
  42. 42.
    Schaffer R. Nonprofit announces plans to deliver loop as supported, FDA-regulated mobile app. 2018; Available at: https://www.healio.com/endocrinology/diabetes/news/print/endocrine-today/%7b2f145aea-96dc-49f2-aba7-605b3bc67de7%7d/nonprofit-announces-plans-to-deliver-loop-as-supported-fda-regulated-mobile-app. Accessed July 11, 2019.
  43. 43.
    US Food and Drug Administration. FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices. 2019; Available at: https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-interoperable-insulin-pump-intended-allow-patients-customize-treatment-through. Accessed June 30, 2019.
  44. 44.
    European Medicines Agency. 2019; Available at: https://www.ema.europa.eu/en/human-regulatory/overview/medical-devices. Accessed June 30, 2019.
  45. 45.
    Polonsky WH, Hessler D, Ruedy KJ, Beck RW, DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017;40(6):736–41.CrossRefGoogle Scholar
  46. 46.
    Juvenile Diabetes Research Foundation. UK still trails Europe and the USA on providing insulin pumps for type 1 diabetes. 2016; Available at: https://jdrf.org.uk/news/uk-still-trails-europe-usa-providing-insulin-pumps-type-1-diabetes/. Accessed July 8, 2019.
  47. 47.
    NHS Digital. National Diabetes Insulin Pump Audit 2016-2017, England and Wales. 2018; Available at: https://files.digital.nhs.uk/80/1E37C4/National%20Diabetes%20Insulin%20Pump%20Audit%20Report%2C%20Main%20Report%2C%202016-2017.pdf. Accessed July 8, 2019.
  48. 48.
    European Commission. New regulations in medical devices. 2018; Available at: https://ec.europa.eu/growth/sectors/medical-devices/new-regulations_en Accessed July 9, 2019.
  49. 49.
    International Consortium of Investigative Journalists. FDA Releases Vast Trove of Hidden Medical Device Injury and Malfunction Reports. 2019; Available at: https://www.icij.org/investigations/implant-files/fda-releases-vast-trove-of-hidden-medical-device-injury-and-malfunction-reports/. Accessed July 15, 2019.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Division of EndocrinologyHouston Methodist HospitalHoustonUSA

Personalised recommendations